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The EAU Urological Infections Guidelines Panel has recently published a large two-part 
systematic review (SR) and meta-analysis (MA) of randomized controlled trials (RCTs) on 
the use of antibiotic and non-antibiotic interventions for the prevention of infectious 
complications related to prostate biopsies (PBs) [1, 2]. The aim of this article is to summarize 
the available evidence and provide clinicians with practical recommendations on how to 
reduce infection rates after PB (Figure 1).  
 
The right indication for & how to minimize unnecessary biopsies 
 
The indication for PB is based on prostate-specific antigen (PSA) level and/or suspicious 
digital rectal examination (DRE) and/or imaging. The decision to perform a biopsy should be 
taken following a PSA control ideally performed in the same laboratory as the original test. 
The patient's age, existing comorbidities and risk stratification should also be considered [3]. 
With the wide availability and increasing experience with prostate MRI, there is growing 
evidence that MRI diagnostics can be used to prevent unnecessary PBs and their associated 
complications [4]. Explicitly, a meta-analysis of 6 RCTs showed that antibiotic therapy for 
PSA reduction is unhelpful and does not prevent unnecessary biopsies [5]. 
 
Patients at risk of developing post-biopsy infections 
 
Personalized Medicine plays a crucial role in contemporary clinical practice. In patients who 
require PBs, personalized medicine requires identifying men at high risk for biopsy-related 
infectious complications beforehand and adapting management accordingly. This will reduce 
peri-procedural morbidity and mortality rates.  
The EAU SR and MA, summarized evidence from a total 143 RCTs reporting multiple risk 
factors (Supplementary Table 1). A notable variation in reported risk factors was observed 
across the studies. Although some of the studies randomized patients with risk factors into 
different arms, clear recommendations on the practical management of patients at high risk 
for PB-complications based on risk stratification could not be provided [1, 2]. 
 
Why you should use transperineal biopsy 
 
A MA of 7 RCTs showed that transperineal PBs were associated with significantly fewer 
infectious complications (RR 0.55, 95% CI: 0.33 to 0.92) compared to transrectal PBs [2]. In 
addition, a SR including 165 studies with 162,577 patients described sepsis rates of 0.1% and 
0.9% for transperineal and transrectal PBs, respectively [6]. A population-based study from 
the UK (n=73,630) showed lower re-admission rates for sepsis in patients who had 
transperineal versus transrectal PBs (1.0% vs 1.4%) [7].  
These results are not surprising, as they align with the surgical principle that the least 
contaminating approach should be followed in order to reduce the rate of infectious 
complications. Available evidence highlights that it is time for the urological community to 
switch from a transrectal to transperineal PB approach despite any possible logistical 
challenges [8]. To date, no RCT has been published investigating different antibiotic 
prophylaxis regimens for transperineal PBs; however, some cohort studies have reported 





Antibiotic prophylaxis in transrectal biopsy – use of fluoroquinolones suspended by the 
European Commission 
 
Perioperative antibiotic prophylaxis with fluoroquinolones was the gold standard for many 
years due to their excellent pharmacokinetics in prostatic tissue and their low resistance rates. 
However, widespread and uncontrolled usage of fluoroquinolones has resulted in increasingly 
high resistance rates. Ultimately, the era of fluoroquinolones in PB prophylaxis was brought 
to an end by the European Commission in March 2019 with the suspension of the indication 
for perioperative antibiotic prophylaxis due to the risks of chronic severe side effects [9]. This 
legally binding decision is applicable in all EU countries. 
If local fluoroquinolone resistance rates are low, fluoroquinolone prophylaxis is possible; 
however, the use of fluoroquinolones in this setting falls outside the EU directive. 
Furthermore, no validated fluoroquinolone resistance threshold has been identified. A 
minimum of a full-day course of fluoroquinolone prophylaxis should be offered, as the MA 
showed that a single dose was significantly inferior [1].  
However, our recent SR showed that empirical prophylaxis with fluoroquinolones was 
inferior to both targeted (RR 1.81, 95% CI: 1.28 to 2.55) and augmented antibiotic 
prophylaxis (RR 2.10, 95% CI: 1.53 to 2.88) [1]. 
 
Antibiotic prophylaxis in transrectal biopsy – alternatives to fluoroquinolones 
 
Regarding alternative options for antibiotic prophylaxis, two RCTs investigated 
aminoglycosides (gentamicin 3 mg/kg i.v. before biopsy; amikacin 15 mg/kg i.m. 1 to 2 h 
before biopsy), two RCTs investigated cephalosporins (ceftriaxone 1 g i.m. 0.5 h before 
biopsy; cefixime 400 mg p.o/day for 3 days starting the day before biopsy) and 3 RCTs 
fosfomycin trometamol (each 3 g p.o. 24 h before plus after biopsy; 3 g p.o. the night before 
biopsy; 3 g p.o. 1 h before biopsy) versus fluoroquinolones. Aminoglycosides and 
cephalosporins were comparable to fluoroquinolones with regard to infectious complications, 
while fosfomycin trometamol led to significantly reduced number of infections (RR 0.49, 
95% CI: 0.27 to 0.87) [1].  
The value of fosfomycin trometamol was confirmed in 3 independent meta-analyses, each 
including 4-5 studies, with non-randomized trials as well as studies conducted in countries 
with high fluoroquinolone resistance [10-12]. In contrast, in a recent large Canadian nested 
case-control study with more than 9000 patients, fosfomycin trometamol (single dose as well 
as two doses) was inferior to ciprofloxacin (3 days or single dose), which limits the 
generalizability of the use of fosfomycin trometamol [13]. In its implementing decision 
C(2020) 3966 final of June 2020, the EU commission sees a positive benefit in the use of 
fosfomycin trometamol as PB antibiotic prophylaxis, but requested additional 
pharmacokinetic and pharmacodynamic studies to support the use of a second dose 24 hours 
after PB.  
 
Targeted prophylaxis was originally introduced to offer an alternative antibiotic agent in case 
of fluoroquinolone resistance from a rectal swab/ stool culture [14]. Fluoroquinolone 
resistance ranged from 18 to 83% in the 6 available RCTs included in the panel’s SR[1]. 
However, 4 out of these 6 studies did not provide detailed information on type, dosage and 
duration of prophylaxis in the targeted prophylaxis group. It remains unclear whether non-
fluoroquinolones were used in cases without fluoroquinolone resistance [1]. Meaning that 
targeted prophylaxis has only been s investigated in the context of fluoroquinolone 
prophylaxis and there is no RCT available to date that does not use fluoroquinolones as 
baseline prophylaxis. 
 
Augmented prophylaxis, describes the use of two or more different classes of antibiotics. 
Although it contradicts the principles of antibiotic stewardship, the reason for its use is the 
broadening of the antibacterial spectrum to cover possible resistance to a single substance. 
However, out of the ten available RCTs on augmented prophylaxis, eight studies combined a 
fluoroquinolone with another antibiotic. Only two older studies used alternative combinations 
(Table 1). Therefore, no recommendation can be made, on the basis of RCTs, as to which 
non-fluoroquinolone using combinations are superior to the use of mono prophylaxis. A 
recent non-RCT multicenter study has investigated the effect of local antibiogram-based 
augmented antibiotic prophylaxis. It reported that the use of an augmented antibiotic 
prophylaxis based on the local resistance patterns could reduce  infectious complications by 
53% relative to the historical rate, but again most combinations included a fluoroquinolone 
[15]. 
 
Non-antibiotic strategies when transrectal biopsy is performed 
 
If a transrectal PB is performed, rectal preparation with povidone-iodine is highly 
recommended, as this is associated with a significantly reduced number of infectious 
complications (RR 0.50, 95% CI 0.38-0.65) [2]. On the other hand, no advantage could be 
shown for the use of an enema [2]. Furthermore, the number of biopsy cores, the use of local 
anaesthesia in the form of periprostatic nerve block (PPNB), number of injections for PPNB, 
needle guide type, needle disinfection, and needle type had no influence on the rate of 
infectious complications [2].  
 
Take home message  
 
The transperineal approach is preferred to reduce PB-related infections. Fluoroquinolones are 
suspended for prophylaxis of PB in the EU; therefore, alternative antibiotics based on local 
resistance, or targeted prophylaxis, in conjunction with povidone-iodine rectal preparation are 




Figure 1 Suggested workflow on how to reduce post biopsy infections. GRADE Working 
Group grades of evidence. 
High certainty: (⊕⊕⊕⊕) we are very confident that the true effect lies close to that of the 
estimate of the effect. 
Moderate certainty: (⊕⊕⊕⊝) we are moderately confident in the effect estimate: the true 
effect is likely to be close to the estimate of the effect, but there is a possibility that it is 
substantially different. 
Low certainty: (⊕⊕⊝⊝) our confidence in the effect estimate is limited: the true effect may 
be substantially different from the estimate of the effect. 
Very low certainty: (⊕⊝⊝⊝) we have very little confidence in the effect estimate: the true 
effect is likely to be substantially different from the estimate of effect. 
 
 
Table 1 Overview of randomized controlled trials investigating standard prophylaxis vs. 
augmented prophylaxis 
Study, Year Patients Country Study period 
Antibiotic classes Detailed prophylaxis 
Standard Augmented Standard Augmented 
Bosquet, 2006 71 vs. 85 Spain 2004 Aminoglycoside 
Aminoglycoside plus 
fluoroquinolone 
TOB 100 mg i.v. 30 min before 
and i.m. 8 h after 
TOB 100 mg i.v. 30 min before 
and i.m. 8 h after plus CIP 500 





China 2007 - 2009 Penicillin 
Penicillin plus 
fluoroquinolone 
AMC 1000 mg p.o. bid for 36 h 
starting 2 h before 
AMC 1000 mg plus CIP 250 
mg p.o. bid for 36 h starting 2 h 
before 




PEF 400 mg p.o. bid for 5 d 
starting 1 d before 
SEC/AZM/FLC p.o. qd for 6 




Egypt 2012-2015 Fosfomycin 
Fluoroquinolone plus 
nitroimidazole 
FOF 3000 mg p.o. 1–2 h before 
CIP 500 mg and MTZ 500 mg 
p.o. 1 h before 
Fong, 1991 47 vs. 54 Canada 1984 - 1989 Cotrimoxazole 
Aminoglycoside plus 
nitroimidazole 
SXT 320 mg/1600 mg p.o. 1 h 
before 
NET 1.5 mg/kg i.v. and MTZ 











CIP 500 mg p.o. bid and MTZ 
500 mg p.o. tid for 5 d starting 
the day before  
CIP 500 mg p.o. bid plus MTZ 
500 mg p.o. tid for 5 d starting 
the day before plus CRO 1 g 
i.v. plus AMK 5mg/kg i.m. 30–




Japan 2007 - 2009 Fluoroquinolone 
Fluoroquinolone plus 
aminoglycoside 
LVX p.o. 2 h before 
LVX p.o. 2 h before plus AMK 
30 min i.v. before 
Pace, 2012 70 vs. 65 Italy 2010 - 2011 Fluoroquinolone 
Fluoroquinolone plus 
cephalosporin 
CIP 1000 mg p.o qd for 5 d 
starting the evening before 
CIP 1000 mg p.o. qd for 5 d 
starting the evening before plus 
CRO 1 g as periprostatic nerve 
block 15 min before biopsy 
Vaz, 1994 10 vs. 10 Brazil Not reported Fluoroquinolone 
Fluoroquinolone plus 
nitroimidazole 
LOM 400 mg p.o. qd for 2 d 
starting 3 h before 
LOM 400 mg p.o. qd plus 
MTZ 500 mg p.o. tid for 2 d 




Egypt 2015 - 2017 Fluoroquinolone 
Fluoroquinolone plus 
aminoglycoside 
CIP 500 mg p.o. bid for 3 d 
starting the day before 
CIP 500 mg p.o. bid for 3 d 
starting the day before plus 
GEN 160 mg i.v. just before 
Amoxicillin-clavulanic acid=AMC, Azithromycin=AZM, Amikacin=AMK, Ciprofloxacin=CIP, 
Ceftriaxone=CRO, Fluconazole=FLC, Fosfomycin=FOF, Gentamycin=GEN, Lomefloxacin=LOM, 
Levofloxacin=LVX, Metronidazole=MTZ, Netilmycin=NET, Pefloxacin=PEF, Secnidazole=SEC, 
Trimethoprim-sulfamethoxazole=SXT, Tobramycin=TOB, qd=once a day, bid= two times a day, tid= three 







Supplementary Table 1 Reported risk factors rendering patients susceptible to develop 
post-biopsy infections  
 
Reported risk factors 
Allergy to antibiotics 
ASA score >3 
Bladder stones 
Chronic prostatitis 
Concomitant or previous antibiotic therapy 
Diabetes mellitus 
Fluoroquinolone resistance 
History of chemotherapy 
Immunosuppression 
Impaired renal or liver function 
Indwelling catheter 
Infections (acute or chronic) of any cause 
Noncompliance with antibiotic prophylaxis 
Previous prostate biopsy 
Previous recent endoscopic manipulation 
Previous sepsis 
Previous urinary retention 
Positive prebiopsy urine culture/leukocyturia/urinary tract infection 
Prosthetic devices 
Severe cardiopulmonary dysfunction 
Transrectal biopsy 
Travel history to countries with high antibiotic resistance  
Uncontrolled hypertension 
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